Philip Wong Wong MD
Critical Care Medicine, Interventional Pulmonology, Pleural Disease
Physician
Join to View Full Profile
4325 Sun N Lake BlvdSebring, FL 33872
Phone+1 863-382-1663
Fax+1 863-386-0162
Dr. Wong is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Pulmonary Disease and Critical Care Medicine, 1999 - 2000- Memorial Sloan Kettering Cancer CenterFellowship, Pulmonary Disease and Critical Care Medicine, 1997 - 1999
Zucker School of Medicine at Hofstra/Northwell at Lenox Hill HospitalResidency, Internal Medicine, 1994 - 1997
St Louis University Sapientia Ae DificatClass of 1992
Certifications & Licensure
CA State Medical License 2006 - 2026
FL State Medical License 2007 - 2026
NY State Medical License 2006 - 2020
TX State Medical License 2007 - 2020
MS State Medical License 2001 - 2016
ND State Medical License 2007 - 2011
NV State Medical License 2006 - 2011
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Pulmonary Disease
- American Board of Internal Medicine Sleep Medicine
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification NextGen Ambulatory EHR, NextGen Healthcare, 2012
Publications & Presentations
PubMed
- 19 citationsBinimetinib plus Gemcitabine and Cisplatin Phase I/II Trial in Patients with Advanced Biliary Cancers.Maeve A. Lowery, Mikaela Bradley, Joanne F. Chou, Marinela Capanu, Scott R. Gerst
Clinical Cancer Research. 2019-02-01 - 14 citationsErratum: anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25.Dalil Hannani, Marie Vétizou, David Enot, Sylvie Rusakiewicz, Nathalie Chaput
Cell Research. 2015-03-01 - 16 citationsAnticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25.Dalil Hannani, Marie Vétizou, David Enot, Sylvie Rusakiewicz, Nathalie Chaput
Cell Research. 2015-02-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
